Troubled Trimeris to liquidate remaining assets

05/11/2008 | News & Observer (Raleigh, N.C.), The

Trimeris has announced it is returning up to $50 million to shareholders and disbursing the rest of its assets by the end of the year. Chief executive Martin Mattingly said the decision is part of Trimeris' "goal of returning value to investors," but a biotech analyst said it signals the gradual liquidation of the biopharmaceutical firm.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC